New Novartis malaria treatment will offer greater access for patients

Sierra Leone Telegraph: 16 July 2015   Novartis, the manufacturer of the malaria treatment drug Coartem, has announced that its Novartis antimalarial medicine Coartem®80 /480mg today received World Health Organization (WHO) prequalification. This makes it the first and only high strength (80/480mg) Artemisinin-based Combination Therapy (ACT) antimalarial treatment, available for [Read More]